Document is current
Any future updates will be listed below
-
Authors
Lahiri, Priyoshi
Young, Daniel
Penner, Regan
Lesack, Kyle https://orcid.org/0000-0003-1291-2376
Dias, Angelica Petersen https://orcid.org/0000-0003-2745-2464
Hannawayya, Rita
De Buck, Jeroen
Orsel, Karin https://orcid.org/0000-0002-6499-5188
Hollenberg, Morley D.
Johnson, Francis
Golub, Lorne
Scaduto, Joseph
Dufour, Antoine https://orcid.org/0000-0002-3429-4188
Cobo, Eduardo R. https://orcid.org/0000-0001-5450-7673
-
Funding
Funding for this research was provided by:
Gouvernement du Canada | Natural Sciences and Engineering Research Council of Canada (RGPAS-2024-04832)
Alberta Agriculture and Forestry (Major Innovation Fund RCP-19-004-MIF)
Agriculture Funding Consortium (Results Driven Agriculture Research (RDAR) 2020F036R)
- License Information
-
More Information
Article History
Received: 12 February 2025
Accepted: 6 October 2025
First Online: 29 October 2025
Competing interests
: The authors declare the following competing interests: Lorne M. Golub is listed as an inventor on several related patents, which have been fully assigned to his institution, Stony Brook University, The State University of New York (SUNY). In the past, he received grants from Stony Brook University, Johnson & Johnson Dental Care Inc., Collagenex Pharma, Inc., and the NY State Diabetes Association, but not during the study. In addition, Dr. Lorne M. Golub also provided consulting in the past for Johnson & Johnson Dental Care Inc. and Collagernex Pharma Inc. Francis Johnson is also listed as an inventor on several related patents, which have been fully assigned to Stony Brook University and Chem-Master International, Inc., on a shared basis. In addition, both Lorne M. Golub and Francis Johnson are minor shareholders in Traverse Biosciences, Inc., and Joseph Scaduto is the president and major shareholder in Traverse Biosciences Inc. They received grants from NIH/NIDCR (Phase II STTR Award 2R42DE024946-02) and Traverse Biosciences Inc. Also, Traverse Biosciences Inc. has exclusively licensed patents from the Research Foundation for the State University of New York (RF/SUNY) covering the structure and use of chemically modified curcumins for commercialization in human and animal health. The authors report no other competing interests in this work.
